APP and its role in AD have been established, in that APP has a short half-life and is metabolized by two distinct antagonist pathways, resulting in cleavage by α secretase to generate sAPPa or β secretase to generate sAPPβ. This evidence concerns the gene APP and Alzheimer disease.